Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Multicenter MC-1 Trial in CABG Surgery
2006-006034-18Phase 3Completed
- Sponsor
- Medicure Inc.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI), coronary arteriosclerosis and myocardial ischemia-reperfusion injury comparing MC-1 with Placebo (2 arms). Primary endpoint: Primary composite endpoint of cardiovascular death or nonfatal myocardial infarction by postoperative day 30. Started Jan 2007; status: completed.
02
Drugs
Tardoxal
03
Conditions
myocardial infarction (MI)coronary arteriosclerosismyocardial ischemia-reperfusion injury
Beyond the preview
Go deeper on 2006-006034-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006034-18.